Klaria Pharmaceutical's drug candidate Epinephrine Alginate Film is being developed as an alternative to injector-pens.  These injection pens are difficult to use and many patients fear using them. As a result, there is a risk that the auto-injector pens are used too late in an anaphylactic shock, causing a potentially life-threatening situation to get more difficult to treat. The injection pens are also difficult to carry and they also generally suffer from poor stability which makes the shelf-life of the products relatively short.  An oral film would be significantly easier to use and could also address many of the other problems with the injector pens.

Jesper Wiklund, CEO of Klaria Pharmaceuticals, said "This payment demonstrates our and our partner Imbrium Therapeutics' continued commitment to developing a new and innovative treatment for patients who are suffering from severe allergies and are at risk of having serious allergic reactions. " Mr. Wiklund continued "This is a commercially significant and very competitive area of research. Together with our partner Imbrium Therapeutics, we have decided to not disclose any further details of the progress we are making in our collaboration, due to competitive reasons."

Klaria has previously received an upfront option payment from Imbrium Therapeutics of USD 3.5 million (SEK 30 million) and is eligible to receive contingent milestone payments with a total value up to USD 66,5 million (SEK 688 million) as well as a double-digit royalty on the United States net sales of Epinephrine Alginate Film.

About Epinephrine Alginate Film (KL-01401)

KL-01401 is an alginate-based oral trans-mucosal film. KL-01401 is the first oral trans-mucosal epinephrine product and is designed to be a significant improvement to all available acute intramuscular injection treatments available to patients today. KL-01401 is a unique molecular dispersion of epinephrine. The KL-01401 film presents epinephrine to the oral mucosal surface in a unique way to allow rapid, consistent absorption without the need for injection. The base film-forming alginate and the epinephrine-containing films have been the subject of comprehensive intellectual property protection, thus ensuring prolonged market exclusivity.

For more information, visit the Klaria Pharma Holding website klaria.com or contact:

Jesper Wiklund, CEO Klaria Pharma Holding AB (publ)

investor.relations@klaria.com

Tel: +46 (0) 8-446 42 99

This is Klaria Pharma Holding AB

Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses.

Klaria is listed on Nasdaq First North Growth Markets under the short name KLAR. FNCA Sweden is Certified Advisor (info@fnca.se,+46(0) 8-528 00 399) for Klaria Pharma Holding AB.

For more information, see www.klaria.com